Cue Biopharma (CUE)
Market Price (2/18/2026): $0.292 | Market Cap: $29.5 MilSector: Health Care | Industry: Biotechnology
Cue Biopharma (CUE)
Market Price (2/18/2026): $0.292Market Cap: $29.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -43% | Weak multi-year price returns2Y Excs Rtn is -125%, 3Y Excs Rtn is -159% | Penny stockMkt Price is 0.3 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -50% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -38 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -537% | |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -26%, Rev Chg QQuarterly Revenue Change % is -36% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 80% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -417%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -420% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -133% | ||
| Key risksCUE key risks include [1] substantial doubt about its ability to continue as a going concern due to a limited cash runway and recurring losses, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -43% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -50% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -125%, 3Y Excs Rtn is -159% |
| Penny stockMkt Price is 0.3 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -38 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -537% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -26%, Rev Chg QQuarterly Revenue Change % is -36% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 80% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -417%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -420% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -133% |
| Key risksCUE key risks include [1] substantial doubt about its ability to continue as a going concern due to a limited cash runway and recurring losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Cue Biopharma (CUE) stock has lost about 60% since 10/31/2025 because of the following key factors:
1. Significant Share Dilution from Public Offering.
Cue Biopharma announced a proposed underwritten public offering on December 18, 2025, and subsequently priced a $10 million public offering on December 19, 2025. This announcement led to a substantial 30% plunge in the stock's after-hours trading, as public offerings typically dilute the value of existing shareholders' stakes.
2. Deteriorating Financial Health and Valuation Concerns.
The company has exhibited significant financial challenges, including a reported three-year revenue growth rate of -29.9% and a current operating margin of -536.72% and net margin of -530.75%. Additionally, its projected enterprise value decreased from $432 million to $211 million, with a distressed Altman Z-Score of -18.7 indicating a high risk of bankruptcy within two years.
Show more
1. Significant Share Dilution from Public Offering.
Cue Biopharma announced a proposed underwritten public offering on December 18, 2025, and subsequently priced a $10 million public offering on December 19, 2025. This announcement led to a substantial 30% plunge in the stock's after-hours trading, as public offerings typically dilute the value of existing shareholders' stakes.
2. Deteriorating Financial Health and Valuation Concerns.
The company has exhibited significant financial challenges, including a reported three-year revenue growth rate of -29.9% and a current operating margin of -536.72% and net margin of -530.75%. Additionally, its projected enterprise value decreased from $432 million to $211 million, with a distressed Altman Z-Score of -18.7 indicating a high risk of bankruptcy within two years.
Show more
Stock Movement Drivers
Fundamental Drivers
The -62.1% change in CUE stock from 10/31/2025 to 2/17/2026 was primarily driven by a -53.2% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.77 | 0.29 | -62.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 7 | -14.3% |
| P/S Multiple | 8.8 | 4.1 | -53.2% |
| Shares Outstanding (Mil) | 95 | 101 | -5.4% |
| Cumulative Contribution | -62.1% |
Market Drivers
10/31/2025 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CUE | -62.1% | |
| Market (SPY) | 0.1% | 15.6% |
| Sector (XLV) | 9.1% | 15.7% |
Fundamental Drivers
The -61.2% change in CUE stock from 7/31/2025 to 2/17/2026 was primarily driven by a -40.7% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.75 | 0.29 | -61.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 7 | -11.2% |
| P/S Multiple | 7.0 | 4.1 | -40.7% |
| Shares Outstanding (Mil) | 74 | 101 | -26.4% |
| Cumulative Contribution | -61.2% |
Market Drivers
7/31/2025 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CUE | -61.2% | |
| Market (SPY) | 8.3% | 18.9% |
| Sector (XLV) | 21.2% | 18.5% |
Fundamental Drivers
The -79.9% change in CUE stock from 1/31/2025 to 2/17/2026 was primarily driven by a -49.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.45 | 0.29 | -79.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 7 | -25.5% |
| P/S Multiple | 7.8 | 4.1 | -46.9% |
| Shares Outstanding (Mil) | 51 | 101 | -49.2% |
| Cumulative Contribution | -79.9% |
Market Drivers
1/31/2025 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CUE | -79.9% | |
| Market (SPY) | 14.5% | 25.4% |
| Sector (XLV) | 8.6% | 24.9% |
Fundamental Drivers
The -91.5% change in CUE stock from 1/31/2023 to 2/17/2026 was primarily driven by a -68.1% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.42 | 0.29 | -91.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 7 | -24.1% |
| P/S Multiple | 12.9 | 4.1 | -68.1% |
| Shares Outstanding (Mil) | 35 | 101 | -64.9% |
| Cumulative Contribution | -91.5% |
Market Drivers
1/31/2023 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CUE | -91.5% | |
| Market (SPY) | 74.2% | 18.3% |
| Sector (XLV) | 23.5% | 17.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CUE Return | -10% | -75% | -7% | -59% | -72% | 0% | -98% |
| Peers Return | 7% | -2% | -1% | 80% | -6% | 3% | 80% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| CUE Win Rate | 50% | 33% | 50% | 25% | 42% | 50% | |
| Peers Win Rate | 51% | 45% | 48% | 52% | 50% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CUE Max Drawdown | -20% | -80% | -40% | -83% | -78% | -9% | |
| Peers Max Drawdown | -17% | -28% | -25% | -20% | -36% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: XNCR, JANX, AMGN, REGN, GILD. See CUE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/17/2026 (YTD)
How Low Can It Go
| Event | CUE | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -90.4% | -25.4% |
| % Gain to Breakeven | 937.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -63.8% | -33.9% |
| % Gain to Breakeven | 176.3% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -74.8% | -19.8% |
| % Gain to Breakeven | 296.6% | 24.7% |
| Time to Breakeven | 365 days | 120 days |
Compare to XNCR, JANX, AMGN, REGN, GILD
In The Past
Cue Biopharma's stock fell -90.4% during the 2022 Inflation Shock from a high on 11/15/2021. A -90.4% loss requires a 937.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cue Biopharma (CUE)
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
AI Analysis | Feedback
- A next-generation Merck (Keytruda) or Bristol Myers Squibb (Opdivo), focused on developing highly precise immunotherapies that 'train' specific immune cells to fight cancer and autoimmune diseases.
- Like a CRISPR Therapeutics or Editas Medicine, but instead of editing genes, they are precisely engineering specific immune cells (T-cells) to treat diseases.
- An early-stage Amgen or Gilead Sciences focused on a unique platform to develop 'smart' biologic drugs that selectively activate or de-activate key immune cells for therapeutic benefit.
AI Analysis | Feedback
- CUE-101: A novel, T cell-selective IL-2-based biologic currently in clinical trials for the treatment of HPV-driven cancers.
- CUE-102: An investigational T cell-selective IL-2-based biologic in preclinical development, designed to target specific tumor antigens for various cancers.
- CUE-300 Series: A pipeline of preclinical biologics being developed to modulate T cell activity for the treatment of autoimmune diseases.
AI Analysis | Feedback
Cue Biopharma (CUE) is a clinical-stage biotechnology company that sells primarily to other companies through collaboration and licensing agreements. It does not sell products directly to individuals.
Its major customers and partners, which provide revenue through research funding, milestone payments, and potential royalties, include:
- Merck KGaA, Darmstadt, Germany: A leading science and technology company operating in healthcare, life science, and electronics. It is important to note that this is a private German company and is distinct from Merck & Co., Inc. (MRK) in the United States.
- LG Chem Life Sciences: This is the life sciences division of LG Chem Ltd., a diversified South Korean chemical company. LG Chem Ltd.'s stock symbol is KRX: 051910 on the Korea Exchange.
AI Analysis | Feedback
Usman “Oz” Azam, M.D. President and Chief Executive Officer
Dr. Azam was appointed President and Chief Executive Officer of Cue Biopharma effective September 29, 2025. He brings over 25 years of leadership experience in drug discovery and development. Most recently, Dr. Azam served as CEO of Inspirna, Inc., a privately held clinical-stage biopharmaceutical company focused on cancer drugs. Prior to Inspirna, he was CEO of Empyrean Neuroscience, a genetic engineering company. As President and CEO of Tmunity Therapeutics, he was involved in developing genetically engineered CAR-T cell therapies. He also served as Global Head of the Cell and Gene Therapies unit at Novartis, where he played a role in the launch of the first FDA-approved CAR-T cell therapy. Dr. Azam has held leadership positions at Pfizer Pharmaceuticals, Aspreva Pharmaceuticals, Johnson & Johnson, and GlaxoSmithKline (GSK).
Currently, Cue Biopharma's official leadership page does not list a Chief Financial Officer. Kerri-Ann Millar, the former CFO, resigned effective June 13, 2025. Daniel Passeri, who was CEO at the time, stepped in as interim Principal Financial and Accounting Officer until a permanent successor could be found. On September 29, 2025, Mr. Passeri transitioned from CEO to Strategic Advisor.
Lucinda Warren Chief Business Officer
Ms. Warren was appointed Chief Business Officer of Cue Biopharma on September 9, 2024. She possesses over 30 years of global experience in the pharmaceutical and biotechnology sectors. Before joining Cue Biopharma, she served as Vice President of Business Development for Neuroscience and Japan Regionally at Johnson & Johnson from 2014 to 2024. In this role, she was responsible for comprehensive business development activities, including licensing, mergers and acquisitions, and alliance management. Her experience also includes significant leadership roles at Janssen Cilag Australia and Centocor/Janssen Biologics.
Matteo Levisetti, M.D. Chief Medical Officer
Dr. Levisetti brings extensive experience in leading global clinical development for pharmaceutical companies of various sizes. Prior to Cue Biopharma, he held the position of Chief Medical Officer at DNAtrix, where he managed clinical operations and regulatory strategy for multiple clinical trials. He also served as Chief Medical Officer at Dauntless Pharmaceuticals and directed immuno-oncology programs as Executive Director of Clinical Development at Mirati Therapeutics. His career includes senior positions with Pfizer, such as Global Clinical Lead, and Global Head & Vice President, Translational Medicine, Immunology and Inflammation at Roche Pharma Research & Early Development.
Daniel Baker, M.D. Interim Chief Development Officer
Dr. Baker serves as the Interim Chief Development Officer at Cue Biopharma.
Colin Sandercock, M.S.E., J.D. Senior Vice President and General Counsel
Mr. Sandercock holds the roles of Senior Vice President and General Counsel at Cue Biopharma.
AI Analysis | Feedback
Key Risks to Cue Biopharma (CUE)
Cue Biopharma (CUE) faces several significant risks to its business, primarily stemming from its financial viability, compliance with listing requirements, and the inherent challenges of being a clinical-stage biotechnology company.
- Substantial Doubt About Going Concern: The most significant risk to Cue Biopharma is the substantial doubt about its ability to continue as a going concern. The company has a history of recurring losses and negative cash flows, with a projected cash runway of less than one year based on current financial data. This financial instability, highlighted by an Altman Z-Score indicating a potential risk of bankruptcy within the next two years, necessitates the company seeking additional capital to fund its operations.
- Nasdaq Listing Non-Compliance: Cue Biopharma has encountered challenges in maintaining compliance with Nasdaq's continued listing requirements, particularly the minimum bid price rule. While the company has recently regained compliance after receiving a deficiency letter, the potential for future non-compliance remains a significant concern. Any delisting could severely impact the stock's market liquidity, diminish the company's ability to secure favorable capital terms, and erode stakeholder confidence.
- Clinical Trial and Regulatory Risks / Dependence on Pipeline Success: As a clinical-stage biotechnology company, Cue Biopharma has not yet generated revenue from product sales and is entirely dependent on the successful development and eventual commercialization of its drug candidates. With only a limited number of drug candidates in clinical trials, setbacks such as negative or inconclusive trial results, delays in regulatory approvals from the U.S. Food and Drug Administration (FDA), or unexpected drug-related side effects, would have a material adverse impact on the company's prospects and financial stability.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Cue Biopharma (CUE) is a clinical-stage biopharmaceutical company, and its future revenue growth over the next 2-3 years is primarily anticipated to be driven by strategic collaborations and the advancement of its therapeutic pipeline. Here are 4 expected drivers of future revenue growth for Cue Biopharma:- Growth in Collaboration Revenue through Upfront Payments and Milestone Achievements: Cue Biopharma has demonstrated a strategy of securing partnerships, which has already led to increased collaboration revenue. The company’s collaboration with Ono Pharmaceutical, established in February 2023, has contributed to this growth. More recently, a partnership with Boehringer Ingelheim concerning CUE-501 included a $12 million upfront payment in Q2 2025 and holds potential for up to $345 million in milestone payments. Additionally, a collaboration with ImmunoScape announced in November 2025 is expected to provide $15 million in upfront payments ($10 million in Q4 2025 and $5 million in November 2026), alongside a 40% equity stake in ImmunoScape and eligibility for high-single-digit royalty payments on net sales. Continued achievement of milestones in these existing collaborations and the formation of new strategic partnerships will be a significant revenue driver.
- Advancement of the Autoimmune Disease Pipeline: Cue Biopharma has strategically refocused its efforts on its autoimmune programs, particularly CUE-401 and the CUE-500 series. CUE-401, developed in collaboration with Ono Pharmaceutical, is progressing with the anticipation of lead candidate selection in Q1 2025 and an intention to advance an Investigational New Drug (IND) submission following positive FDA feedback. The CUE-500 series is being positioned for strategic partnering to address B-cell-mediated autoimmune diseases. Successful progression of these candidates through preclinical and early clinical stages is expected to trigger further collaboration and milestone payments.
- Strategic Partnering for Oncology Programs: While Cue Biopharma has downsized its direct investment in oncology programs to focus on autoimmune diseases, it intends to preserve the potential value of its clinical oncology programs, CUE-101 and CUE-102, by pursuing partnerships. CUE-101 has shown promising clinical activity in Phase 1 trials for HPV+ recurrent/metastatic head and neck squamous cell carcinoma, both as a monotherapy and in combination with KEYTRUDA®. Securing new out-licensing or co-development agreements for these oncology assets would generate upfront payments, milestone payments, and potential future royalties.
- Expansion and Diversification of the Immuno-STAT Platform into New Indications: The company's proprietary Immuno-STAT™ platform is described as modular and versatile, designed to selectively engage and modulate targeted T cells for a broad range of indications beyond oncology, including autoimmune and infectious diseases. This inherent flexibility of the platform creates opportunities for Cue Biopharma to discover and develop new therapeutic candidates and enter into additional collaborations across various therapeutic areas, further diversifying its potential revenue streams.
AI Analysis | Feedback
Share Issuance
- In April 2025, Cue Biopharma raised approximately $20 million in gross proceeds through a public offering of common stock and accompanying warrants, including pre-funded warrants.
- As of September 30, 2024, the company had sold 9,028,573 shares of common stock under an At-The-Market (ATM) agreement initiated in October 2021, yielding $40.4 million in net proceeds.
- In November 2022, Cue Biopharma completed a Post IPO funding round for $30 million.
Inbound Investments
- In April 2025, Cue Biopharma entered a strategic collaboration and license agreement with Boehringer Ingelheim for its CUE-501 candidate, receiving a $12 million upfront payment and eligible for up to approximately $345 million in potential milestone payments.
- In November 2025, Cue Biopharma announced a strategic collaboration with ImmunoScape, entitling Cue Biopharma to an upfront payment of $15 million ($10 million in Q4 2025 and $5 million in November 2026), a 40% equity stake in ImmunoScape, and high-single-digit royalties on net sales.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CUE.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 84.24 |
| Mkt Cap | 41.3 |
| Rev LTM | 7,247 |
| Op Inc LTM | 1,832 |
| FCF LTM | 1,868 |
| FCF 3Y Avg | 1,811 |
| CFO LTM | 2,475 |
| CFO 3Y Avg | 2,314 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.9% |
| Rev Chg 3Y Avg | 8.8% |
| Rev Chg Q | 5.8% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | -33.3% |
| Op Mgn 3Y Avg | -49.3% |
| QoQ Delta Op Mgn LTM | 0.8% |
| CFO/Rev LTM | -30.8% |
| CFO/Rev 3Y Avg | -33.9% |
| FCF/Rev LTM | -34.9% |
| FCF/Rev 3Y Avg | -41.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 41.3 |
| P/S | 5.7 |
| P/EBIT | 7.4 |
| P/E | 8.7 |
| P/CFO | 7.7 |
| Total Yield | -3.2% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | -1.3% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.3% |
| 3M Rtn | -9.3% |
| 6M Rtn | 31.3% |
| 12M Rtn | -5.4% |
| 3Y Rtn | -9.3% |
| 1M Excs Rtn | 7.5% |
| 3M Excs Rtn | -4.0% |
| 6M Excs Rtn | 24.8% |
| 12M Excs Rtn | -17.3% |
| 3Y Excs Rtn | -77.1% |
Price Behavior
Price Behavior
| Market Price | $0.29 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/02/2018 | |
| Distance from 52W High | -80.5% | |
| 50 Days | 200 Days | |
| DMA Price | $0.36 | $0.64 |
| DMA Trend | down | down |
| Distance from DMA | -19.1% | -54.6% |
| 3M | 1YR | |
| Volatility | 139.3% | 96.6% |
| Downside Capture | 258.43 | 189.94 |
| Upside Capture | -177.67 | -1.88 |
| Correlation (SPY) | 14.0% | 24.9% |
CUE Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.56 | 0.81 | 1.75 | 1.76 | 1.25 | 1.25 |
| Up Beta | 18.01 | 6.11 | 3.87 | 2.81 | 1.20 | 1.61 |
| Down Beta | 0.91 | 3.32 | 4.01 | 4.27 | 1.80 | 2.07 |
| Up Capture | 228% | -376% | -193% | -64% | -1% | 1% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 9 | 13 | 23 | 55 | 109 | 322 |
| Down Capture | 60% | 123% | 221% | 146% | 132% | 103% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 28 | 38 | 69 | 138 | 413 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CUE | |
|---|---|---|---|---|
| CUE | -79.9% | 96.8% | -1.23 | - |
| Sector ETF (XLV) | 9.0% | 17.4% | 0.34 | 24.8% |
| Equity (SPY) | 13.0% | 19.4% | 0.51 | 25.1% |
| Gold (GLD) | 67.2% | 25.5% | 1.99 | 13.0% |
| Commodities (DBC) | 5.2% | 16.8% | 0.13 | 17.3% |
| Real Estate (VNQ) | 7.8% | 16.6% | 0.28 | 24.3% |
| Bitcoin (BTCUSD) | -28.8% | 44.9% | -0.62 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CUE | |
|---|---|---|---|---|
| CUE | -55.2% | 96.2% | -0.41 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 18.6% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 24.1% |
| Gold (GLD) | 21.3% | 17.1% | 1.02 | 6.9% |
| Commodities (DBC) | 10.2% | 18.9% | 0.42 | 9.4% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | 18.5% |
| Bitcoin (BTCUSD) | 8.2% | 57.2% | 0.36 | 13.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CUE | |
|---|---|---|---|---|
| CUE | -30.9% | 88.4% | -0.12 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 22.9% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 26.8% |
| Gold (GLD) | 14.8% | 15.6% | 0.79 | 7.8% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 12.9% |
| Real Estate (VNQ) | 6.8% | 20.7% | 0.29 | 19.7% |
| Bitcoin (BTCUSD) | 68.5% | 66.7% | 1.08 | 14.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -7.2% | -13.1% | -30.7% |
| 8/12/2025 | 2.6% | 3.3% | -3.1% |
| 3/31/2025 | -17.7% | -31.3% | -17.1% |
| 5/9/2024 | -9.1% | -9.1% | -24.8% |
| 3/17/2020 | -13.7% | 22.7% | 63.3% |
| SUMMARY STATS | |||
| # Positive | 1 | 2 | 1 |
| # Negative | 4 | 3 | 4 |
| Median Positive | 2.6% | 13.0% | 63.3% |
| Median Negative | -11.4% | -13.1% | -21.0% |
| Max Positive | 2.6% | 22.7% | 63.3% |
| Max Negative | -17.7% | -31.3% | -30.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/21/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/16/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sarraf, Pasha | Direct | Buy | 1022026 | 0.31 | 323,857 | 99,747 | 99,747 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.